N
Nutriband Inc. (NTRB)
NCM – Real Time Price. Currency in USD
3.06
+0.03 (0.99%)
At close: Jun 26, 2026, 4:00 PM EDT
3.06
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.06
+0.03 (0.99%)
At close: Jun 26, 2026, 4:00 PM EDT
3.06
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
| Name | Position |
|---|---|
| Dr. Alan Smith Ph.D. | COO & President of 4P Therapeutics |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer |
| Mr. Gareth Sheridan | Founder, CEO & Director |
| Mr. Gerald Goodman | CFO & Chief Accounting Officer |
| Mr. Michael Myer | President of Pocono Pharmaceutical |
| Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman |
| Mr. Tyler Overk | Head of Active Intelligence |
| Date | Type | Document |
|---|---|---|
| 2026-06-11 | 10-Q | ea0294013-10q_nutriband.htm |
| 2026-05-18 | 10-K/A | ea0290874-10ka1_nutriband.htm |
| 2026-04-29 | 10-K | ea0287168-10k_nutriband.htm |
| 2026-04-07 | 8-K | ea0285330-8k_nutriband.htm |
| 2026-02-13 | 8-K | ea0277156-8k_nutriband.htm |
| 2026-02-03 | 8-K | ea0275277-8k_nutriband.htm |
| 2025-12-30 | 8-K | ea0271298-8k_nutriband.htm |
| 2025-12-19 | DEF 14A | ea0267930-01.htm |
| 2025-12-11 | 10-Q | ea0268722-10q_nutriband.htm |
| 2025-10-28 | 8-K | ea0262795-8k_nutriband.htm |